Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required.
The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed.
MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.
Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.
The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed.
MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.
Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.
Location: United Kingdom, England, Bedford
Employees: 11-50
Phone: +44 1234 589725
Total raised: $9.38M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Bioscience... | bioscience... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.07.2020 | - | $6.95M | - |
| 08.05.2018 | Series A | $2.03M | - |
| 30.06.2017 | - | $390.82K | - |
Mentions in press and media 10
| Date | Title | Description |
| 11.03.2022 | Industry heavyweights join MIP Diagnostics Board | Following the announcement of a follow on investment round of £4.3million, MIP Diagnostics has announced the appointment of two new directors to its Board. |
| 28.02.2022 | Mercia announces further direct investment into MIP Diagnostics | Mercia is pleased to announce completion of a second tranche investment round of £4.3million into existing direct investment portfolio company, MIP Diagnostics Limited, a UK-based nanotechnology business. |
| 20.04.2021 | ‘Plastic antibodies’ could improve success of rapid COVID tests | A biotech company which produces synthetic antibodies has launched a new product that could improve the success of rapid sensors in detecting Covid-19. |
| 14.07.2020 | MIP Diagnostics Completes £5.1M Funding Round | MIP Diagnostics, a Bedfordshire, UK-based nanotechnology business, completed a £5.1m funding round. The round was led by Downing Ventures, with participation from BGF, Mercia and Calculus VCT. The company intends to use the funds to acceler... |
| 10.05.2018 | ‘Synthetic antibody’ firm secures Series A investment | A Midlands-based life sciences company which develops synthetic alternatives to antibodies has closed a £1.5m Series A funding round supported by Mercia Fund Managers and a number of private investors. |
| 08.05.2018 | MIP Diagnostics Secures £1.5M in Series A Funding | MIP Diagnostics, an East Midlands, UK-based synthetic antibody company, secured £1.5m in Series A funding. Backers included Mercia Fund Managers and a number of private investors including Andrew Fisher and David Evans. The company intends ... |
| 30.06.2017 | MIP Diagnostics Receives £300K Follow-On Funding | MIP Diagnostics, a Leicester, UK-based life sciences startup that develops “plastic antibodies” for a variety of applications, received a £300k follow-on funding. Mercia Fund Management made the investment. MIP Diagnostics, a spin-out from ... |
| - | The time to put the spotlight on Healthcare is now | As Covid-19 continues to dominate the global agenda, early-stage UK technology companies in the healthcare and life sciences sectors are at the forefront of making the world a safer and more secure place to live in. The need for accelera... |
| - | MIP Diagnostics launches synthetic antibody solution for high sensitivity COVID-19 rapid testing | BGF portfolio company, MIP Diagnostics Ltd. this week announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detect... |
| - | MIP Diagnostics secures £5.1m in funding | Nanotechnology business, MIP Diagnostics, has completed a £5.1m funding round to accelerate its global expansion. The co-investment has come from Mercia Asset Management, a founding investor and the largest shareholder in the company, and w... |